Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 5/20 | 0.62 |
| ▸ | PRKCG | P05129 | 5/20 | 0.62 |
| ▸ | PRKCB | P05771 | 5/20 | 0.62 |
| ▸ | PRKCA | P17252 | 5/20 | 0.62 |
| ▸ | PRKCH | P24723 | 5/20 | 0.62 |
| ▸ | PRKCI | P41743 | 5/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.62 |
| ▸ | PRKACA | P17612 | 2/20 | 0.62 |
| ▸ | PRKACG | P22612 | 2/20 | 0.62 |
| ▸ | PRKACB | P22694 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415921 | 1.00 | PRKD3 (0.62) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3959789 | 0.98 | PRKD3 (0.61) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3148480 | 0.92 | NPC1 (0.61) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL31615194 | 0.92 | NPC1 (0.61) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3908537 | 0.88 | PRKD3 (0.59) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL6417753 | 0.88 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL12424814 | 0.85 | KDR (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL2986726 | 0.85 | PRKD3 (0.53) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3257968 | 0.84 | PRKD3 (0.49) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL15758300 | 0.83 | PRKCB (0.64) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4739678-A2 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | Memorial Sloan Kettering Cancer Center (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260125647-A1 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-07 | — | — | US | claimed |
| EP-4627596-A1 | AN INTEGRATIVE FRAMEWORK TO IDENTIFY THERAPEUTIC MOLECULES FOR TREATING PRETERM BIRTH | The Regents of University of California (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250268913-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH CTM TARGETING | SMARTDYELIVERY GMBH (DE) | 2025-08-28 | — | — | US | claimed |
| US-12215355-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | claimed |
| WO-2025010366-A2 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-01-09 | — | — | WO | claimed |
| US-20250002843-A1 | DERIVATION OF NAÏVE BOVINE EMBRYONIC STEM CELLS | THE SEMEX ALLIANCE (CA) | 2025-01-02 | — | — | US | claimed |
| EP-4461806-A2 | SC-B CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | President and Fellows of Harvard College (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-31 | — | — | US | claimed |
| WO-1997040842-A1 | USE OF PROTEIN KINASE C INHIBITORS TO ENHANCE THE CLINICAL EFFICACY OF ONCOLYTIC AGENTS AND RADIATION THERAPY | ELI LILLY AND COMPANY (US) | 1997-11-06 | — | — | WO | claimed |
| WO-1997040831-A1 | THERAPEUTIC TREATMENT FOR VEGF RELATED OCCULAR DISEASES | ELI LILLY AND COMPANY (US) | 1997-11-06 | — | — | WO | claimed |
| WO-1997034890-A1 | SYNTHESIS OF INDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1997-09-25 | — | — | WO | claimed |
| WO-1997030174-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-21 | — | — | WO | claimed |
| EP-0776899-A1 | Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1997-06-04 | — | — | EP | claimed |
| WO-1997019080-A1 | NOVEL INTERMEDIATES AND THEIR USE TO PREPARE N,N'-BRIDGED BISINDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1997-05-29 | — | — | WO | claimed |
| WO-1996030348-A1 | SYNTHESIS OF BIS-INDOLYLMALEIMIDES | ELY LILLY AND COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| US-5554608-A | INHIBITOR OF PROTEIN KINASE C | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 1996-09-10 | — | — | US | claimed |
| EP-0674632-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | claimed |
| WO-1994014798-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | Gödecke Aktiengesellschaft (DE) | 1994-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125647-A1 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | CDK3, CDK5, PRKD3 | PRKD3 3/4885PRKCG 56/4885PRKCB 29/4885 |
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | RPS6KA3, RPS6KA1, CDK9 | PRKD3 45/4885PRKCG 144/4885PRKCB 49/4885 |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | EBP, AKT3, PRKCD | PRKD3 34/4885PRKCG 24/4885PRKCB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.